Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingying 2 is a Traditional Chinese Medicine (TCM) hospital preparation developed by the Shanghai Municipal Hospital of Traditional Chinese Medicine for the treatment of Hashimoto's thyroiditis. Formulated as a decoction or granules, it is designed to address the TCM patterns of phlegm-stasis and liver-qi stagnation, which are frequently associated with autoimmune thyroid disorders. Clinical research indicates that Qingying 2 modulates the immune system by significantly reducing the serum levels of thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibodies (TGAb). It is also thought to regulate the balance of T-helper cell subsets, such as Th1/Th2 and Treg/Th17 ratios, thereby reducing thyroid inflammation and volume while improving clinical symptoms in patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qingying 2.